clinical trial · NCT06585449
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
Huntington's DiseaseALN-HTT02Placebo
brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
started
Oct 14, 2024
primary completion
Jul 5, 2028
completion
Jul 5, 2028
last updated
Mar 31, 2026
official title
A Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered Single Ascending Doses of ALN-HTT02 in Adult Patients With Huntington's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol